Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3

• Published in: Journal of clinical oncology Vol. 42; no. 11; pp. e23 - e43
• Main Authors: Jaiyesimi, Ishmael A, Leighl, Natasha B, Ismaila, Nofisat, Alluri, Krishna, Florez, Narjust, Gadgeel, Shirish, Masters, Gregory, Schenk, Erin L, Schneider, Bryan J, Sequist, Lecia, Singh, Navneet, Bazhenova, Lyudmila, Blanchard, Elizabeth, Freeman-Daily, Janet, Furuya, Naoki, Halmos, Balazs, Azar, Ibrahim Hanna, Kuruvilla, Sara, Mullane, Michael, Naidoo, Jarushka, Reuss, Joshua E, Spigel, David R, Owen, Dwight H, Patel, Jyoti D
• Format: Journal Article
• Language: English
• Published: United States 10.04.2024
• ISSN: 0732-183X; 1527-7755; 1527-7755
• DOI: 10.1200/JCO.23.02746

To provide evidence-based recommendations for patients with stage IV non-small cell lung cancer (NSCLC) without driver alterations. This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized clinical trials (RCTs), with the latest time frame spanning February to October 2023. An Expert Panel of medical oncology, pulmonary, community oncology, research methodology, and advocacy experts were convened. The literature search included systematic reviews, meta-analyses, and randomized controlled trials. Outcomes of interest include efficacy and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Ten new RCTs were identified in the latest search of the literature to date. Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients without driver alterations.Additional information is available at www.asco.org/living-guidelines.